Gisela M. Schwab's Insider Trades & SAST Disclosures
Gisela M. Schwab's most recent trade in Exelixis Inc was a trade of 40,000 Option (right to buy) done . Disclosure was reported to the exchange on July 26, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gisela M. Schwab.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.20 per share. | 26 Jul 2021 | 40,000 | 689,078 (0%) | 0% | 4.2 | 168,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 50,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 26 Apr 2021 | 50,000 | 613,482 (0%) | 0% | 25 | 1,250,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 26 Apr 2021 | 50,000 | 663,482 (0%) | 0% | 1.7 | 85,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 72,885 | 613,482 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 50,000 | 150,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 50,000 | 100,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 17 Feb 2021 | 50,000 | 590,597 (0%) | 0% | 1.7 | 85,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 17 Feb 2021 | 50,000 | 540,597 (0%) | 0% | 22.5 | 1,125,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 17 Feb 2021 | 50,000 | 590,597 (0%) | 0% | 1.7 | 85,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 22.35 per share. | 17 Feb 2021 | 50,000 | 540,597 (0%) | 0% | 22.4 | 1,117,500 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.91 per share. | 15 Feb 2021 | 2,858 | 540,597 (0%) | 0% | 21.9 | 62,619 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 71,293 | 558,437 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.56 per share. | 03 Feb 2021 | 14,982 | 543,455 (0%) | 0% | 22.6 | 337,994 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 9,745 | 487,144 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 9,685 | 479,982 (0%) | 0% | 20.2 | 195,250 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 2,685 | 489,667 (0%) | 0% | 20.2 | 54,130 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 2,583 | 477,399 (0%) | 0% | 20.2 | 52,073 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2020 | 213,879 | 547,070 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.79 per share. | 22 Oct 2020 | 55,235 | 491,835 (0%) | 0% | 21.8 | 1,203,571 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 9,745 | 335,708 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.58 per share. | 02 Sep 2020 | 2,517 | 333,191 (0%) | 0% | 21.6 | 54,317 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 22.96 per share. | 04 Jun 2020 | 100,000 | 325,963 (0%) | 0% | 23.0 | 2,296,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 100,000 | 200,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 04 Jun 2020 | 100,000 | 425,963 (0%) | 0% | 1.7 | 170,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 23 Apr 2020 | 100,000 | 425,122 (0%) | 0% | 1.7 | 170,000 | Common Stock |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2020 | 100,000 | 300,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Gisela M. Schwab | Pres, Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 23 Apr 2020 | 100,000 | 325,122 (0%) | 0% | 26 | 2,600,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges